MedTrace Logo

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

NCT03406949 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2022-05-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of obrindatamab administered in combination with retifanlimab in patients with B7-H3- expressing tumors.

Conditions

Interventions

BIOLOGICAL

obrindatamab

B7-H3 x CD3 DART protein

BIOLOGICAL

retifanlimab

anti-PD-1 antibody

Sponsors & Collaborators

Principal Investigators

  • Stephen L Eck, M.D. · MacroGenics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-27
Primary Completion
2022-04-27
Completion
2022-04-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03406949 on ClinicalTrials.gov